What's happening
Reference profile
Generated 13:13 ET
ACTU — Actuate Therapeutics, Inc. Common stock is down 4.2%, at 0.58, on $324.0K traded, 1.5× 20-day volume, 0.06× float rotation. Score 64. Primary driver: 5.8% float rotation. Supply intelligence: clean gap · 78.
Get alerts on $ACTU
Halts, resumptions, new filings, and updated reports — in your inbox within minutes of the event.
Free · one email per event, no digests or spam · unsubscribe anytime · joins real followers
Free float
9.7M
2026-08-14
Shares out
24.0M
latest detail
Market cap
$14.5M
at ref price
Short interest
13.7%
2026-09-30
Float rotation
0.06×
latest snapshot
20d dollar vol
$253.5K
baseline
Gap quality
clean gap · 78
live supply-pressure model
Supply factor
low float
detector reason
Supply factor
elevated short interest
detector reason
Supply factor
nano-cap supply profile
detector reason
This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.
2026-10-19 13:10 ETSignalActuate Therapeutics, Inc. Common stock is down 4.2%, at 0.58, on $324.0K traded, 1.5× 20-day volume, 0.06× float rotation. Score 64. Primary driver: 5.8% float rotation. Supply intelligence: clean gap · 78.
2026-06-01 07:00 ETFDA / ClinicalActuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer News
2026-05-118-KItem 7.01 — Regulation FD disclosure; Item 9.01 — Financial statements and exhibits SEC
2026-03-04 17:00 ETFDA / ClinicalActuate Therapeutics to Present at The Citizens Life Sciences Conference News
2025-09-11 16:01 ETOfferingActuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option News
2025-05-31 16:30 ETFDA / ClinicalActuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer News
Latest detector signalscore 64